《Breast Cancer Research And Treatment》重点专注发布医学-肿瘤学领域的新研究，旨在促进和传播该领域相关的新技术和新知识。鼓励该领域研究者详细地发表他们的高质量实验研究和理论结果。该杂志创刊至今，在医学-肿瘤学领域，有较高影响力，对来稿文章质量要求较高，稿件投稿过审难度较大。欢迎广大同领域研究者投稿该杂志。
| CiteScore | SJR | SNIP | CiteScore排名 | |||
|---|---|---|---|---|---|---|
| 6.8 | 1.267 | 1.019 | 学科类别 | 分区 | 排名 | 百分位 |
|
大类：大类：Medicine
小类：小类：Oncology
|
Q2 | 103/404 | 74% | |||
|
大类：大类：Medicine
小类：小类：CancerResearch
|
Q2 | 90/230 | 61% | |||
| 按JIF指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
|---|---|---|---|---|
| 学科：ONCOLOGY | SCIE | Q2 | 142 / 322 | 56.1% |
| 按JCI指标学科分区 | 收录子集 | 分区 | 排名 | 百分位 |
|---|---|---|---|---|
| 学科：ONCOLOGY | SCIE | Q2 | 135 / 322 | 58.23% |
文章名称
引用次数
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
96
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
58
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
50
Rapid review: radiomics and breast cancer
29
Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)
29
Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals
28
Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy
28
Clinical implications of germline mutations in breast cancer: TP53
26
Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study
25
Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers
25
国家/地区
发文量
TUSA
690
TEngland
235
TCHINA MAINLAND
151
TCanada
135
TGERMANY (FED REP GER)
103
TNetherlands
102
TItaly
94
TSouth Korea
76
TJapan
75
TFrance
63
